Latest From Zydus Cadila
The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
Coronavirus Update: AstraZeneca To Develop Oxford’s Vaccine, Adaptive Trial Delivers Remdesivir's Good News
AstraZeneca is to develop and distribute Oxford's COVID-19 vaccine candidate in collaboration with Vaccitech. Its developers believe it could be available as early as September.
A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Zydus Cadila
- Senior Management
- Pankaj R Patel, Chmn. & Managing Dir.
- Contact Info
Phone: (91) 79 26868100
Zydus Tower, Satellite Cross Roads
Ahmedabad , 380015